Cargando…

Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease

A significant number of cardiovascular disease (CVD) patients, with the target lipid levels, as set by the guidelines, achieved, continue to remain at risk. In this setting, lipoprotein (Lp) a role in CVD prognosis is regaining interest. Although Lp(a) is related to the arteriosclerotic process, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoursalas, Athanasios, Tsarouhas, Konstantinos, Tsitsimpikou, Christina, Kolovou, Genovefa, Vardavas, Alexander, Hoursalas, Ioannis, Spandidos, Demetrios A., Milionis, Haralampos, Elisaf, Moses, Tsiara, Stavroula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199069/
https://www.ncbi.nlm.nih.gov/pubmed/35720629
http://dx.doi.org/10.3892/etm.2022.11371
_version_ 1784727776354369536
author Hoursalas, Athanasios
Tsarouhas, Konstantinos
Tsitsimpikou, Christina
Kolovou, Genovefa
Vardavas, Alexander
Hoursalas, Ioannis
Spandidos, Demetrios A.
Milionis, Haralampos
Elisaf, Moses
Tsiara, Stavroula
author_facet Hoursalas, Athanasios
Tsarouhas, Konstantinos
Tsitsimpikou, Christina
Kolovou, Genovefa
Vardavas, Alexander
Hoursalas, Ioannis
Spandidos, Demetrios A.
Milionis, Haralampos
Elisaf, Moses
Tsiara, Stavroula
author_sort Hoursalas, Athanasios
collection PubMed
description A significant number of cardiovascular disease (CVD) patients, with the target lipid levels, as set by the guidelines, achieved, continue to remain at risk. In this setting, lipoprotein (Lp) a role in CVD prognosis is regaining interest. Although Lp(a) is related to the arteriosclerotic process, there is not currently an adequate amount of data for the inclusion of Lp(a) levels as a primary therapeutic target in the treatment of coronary artery disease (CAD) patients. In this framework, the current retrospective study aims to investigate the association of Lp(a) levels with the adverse cardiovascular (CV) events presented in a 10 year follow-up of CVD patients with dyslipidemia and its association with the major CV risk factors. A statistically significant reduction in Lp(a) levels was observed during the follow-up period (72.8±45.6 vs. 68.3±41.8 mg/dl; McNemar test; P<0.001). The vast majority of patients who suffered a new acute myocardial infarction during the follow up period had Lp(a) levels >30 mg/dl (24/28 patients, mean ± standard deviation Lp(a), 83.1±36.6 mg/dl, P=0.001). Kaplan-Meier survival analysis did not find statistically significant differences in a percutaneous coronary intervention (PCI) time occurrence during the follow-up period between patients with low (≤30 mg/dl) and high (>30 mg/dl) Lp(a) levels (log-rank P=0.305). On the other hand, when a second and third PCI conducted during the monitoring period were included in the Kaplan Meier analysis as events, the mean time for a PCI was significantly shorter (7.2%; P=0.01) for patients with Lp(a) levels >30 mg/dl. In conclusion, the current study reported that patients with high Lp(a) values are more prone to the occurrence of new myocardial infarction, while the Lp(a) cut-off value of 30 mg/dl was linked in CVD patients to an earlier need for PCI, especially in the most vulnerable group of patients with more than one (recurrent) revascularizations.
format Online
Article
Text
id pubmed-9199069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-91990692022-06-17 Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease Hoursalas, Athanasios Tsarouhas, Konstantinos Tsitsimpikou, Christina Kolovou, Genovefa Vardavas, Alexander Hoursalas, Ioannis Spandidos, Demetrios A. Milionis, Haralampos Elisaf, Moses Tsiara, Stavroula Exp Ther Med Articles A significant number of cardiovascular disease (CVD) patients, with the target lipid levels, as set by the guidelines, achieved, continue to remain at risk. In this setting, lipoprotein (Lp) a role in CVD prognosis is regaining interest. Although Lp(a) is related to the arteriosclerotic process, there is not currently an adequate amount of data for the inclusion of Lp(a) levels as a primary therapeutic target in the treatment of coronary artery disease (CAD) patients. In this framework, the current retrospective study aims to investigate the association of Lp(a) levels with the adverse cardiovascular (CV) events presented in a 10 year follow-up of CVD patients with dyslipidemia and its association with the major CV risk factors. A statistically significant reduction in Lp(a) levels was observed during the follow-up period (72.8±45.6 vs. 68.3±41.8 mg/dl; McNemar test; P<0.001). The vast majority of patients who suffered a new acute myocardial infarction during the follow up period had Lp(a) levels >30 mg/dl (24/28 patients, mean ± standard deviation Lp(a), 83.1±36.6 mg/dl, P=0.001). Kaplan-Meier survival analysis did not find statistically significant differences in a percutaneous coronary intervention (PCI) time occurrence during the follow-up period between patients with low (≤30 mg/dl) and high (>30 mg/dl) Lp(a) levels (log-rank P=0.305). On the other hand, when a second and third PCI conducted during the monitoring period were included in the Kaplan Meier analysis as events, the mean time for a PCI was significantly shorter (7.2%; P=0.01) for patients with Lp(a) levels >30 mg/dl. In conclusion, the current study reported that patients with high Lp(a) values are more prone to the occurrence of new myocardial infarction, while the Lp(a) cut-off value of 30 mg/dl was linked in CVD patients to an earlier need for PCI, especially in the most vulnerable group of patients with more than one (recurrent) revascularizations. D.A. Spandidos 2022-05-13 /pmc/articles/PMC9199069/ /pubmed/35720629 http://dx.doi.org/10.3892/etm.2022.11371 Text en Copyright: © Hoursalas et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Hoursalas, Athanasios
Tsarouhas, Konstantinos
Tsitsimpikou, Christina
Kolovou, Genovefa
Vardavas, Alexander
Hoursalas, Ioannis
Spandidos, Demetrios A.
Milionis, Haralampos
Elisaf, Moses
Tsiara, Stavroula
Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease
title Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease
title_full Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease
title_fullStr Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease
title_full_unstemmed Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease
title_short Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease
title_sort moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199069/
https://www.ncbi.nlm.nih.gov/pubmed/35720629
http://dx.doi.org/10.3892/etm.2022.11371
work_keys_str_mv AT hoursalasathanasios moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease
AT tsarouhaskonstantinos moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease
AT tsitsimpikouchristina moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease
AT kolovougenovefa moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease
AT vardavasalexander moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease
AT hoursalasioannis moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease
AT spandidosdemetriosa moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease
AT milionisharalampos moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease
AT elisafmoses moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease
AT tsiarastavroula moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease